Pfizer has signed its second antibody discovery deal of January 2011, this time partnering with Seattle-based Theraclone Sciences. Pfizer will gain access to Theraclone’s I-STAR™ antibody discovery technology to discover natural human monoclonal antibodies against up to four selected targets for cancer and infectious diseases. The deal is Theraclone’s first major collaboration and the company will receive research funding and success-based milestones that together total up to US$632 M, along with undisclosed royalties. Pfizer will be responsible for the preclinical and clinical development of the therapeutic antibody drug candidates.